Manasi Jaiman, Chief Medical Officer of Aardvark Therapeutics, Inc. (NASDAQ:AARD), filed a Form 4 on November 10, 2026, reporting the repricing of three stock option grants on November 6, 2026, reducing their exercise prices to $1.26 per share from original prices of $13.48, $11.29, and $4.24.

Key Highlights

  • Three options repriced: Stock options covering 70,549, 126,999, and 177,012 shares of common stock had their exercise prices reduced to $1.26 per share on November 6, 2026.
  • Original exercise prices: The three options carried prior exercise prices of $13.48, $11.29, and $4.24, respectively.
  • Stockholder approval: According to the filing, stockholders approved the repricing proposal on August 14, 2026.
  • Retention Period condition: The new exercise price of $1.26 applies only if the reporting person remains in continuous service from November 6, 2026 until the earlier of November 6, 2027 or a qualifying Change in Control.
  • Pre-retention exercise price: If any repriced option is exercised before the end of the Retention Period, the original, higher exercise price applies rather than $1.26.
  • Vesting schedules unchanged: According to the filing, each repriced option retains its respective original vesting schedule and expiration date.

Aardvark Therapeutics CMO Stock Option Repricing Details

According to the Form 4 filed with the SEC, Manasi Jaiman, serving as Chief Medical Officer of Aardvark Therapeutics, Inc. (NASDAQ:AARD), reported six derivative security transactions on November 6, 2026, all reflecting the repricing of existing stock options. Each of the three repriced options was recorded as both a disposition of the old option at its original exercise price and an acquisition of a replacement option at the new exercise price of $1.26 per share.

The filing states that on August 14, 2026, the company's stockholders approved a proposal to reprice certain eligible outstanding stock options. In accordance with that approval, the exercise price of each eligible option was reduced to $1.26, described in the filing as the "New Exercise Price." The repriced options had expiration dates of February 9, 2036, June 11, 2035, and August 31, 2034, covering 70,549, 126,999, and 177,012 shares of common stock, respectively. Following the transactions, the reporting person directly holds all three repriced options.

The filing specifies a "Retention Period" running from November 6, 2026 until the earlier of November 6, 2027 or a Change in Control occurring during the reporting person's continuous service. If any repriced option is exercised before the Retention Period ends, the exercise price reverts to the original, higher price for that option. The vesting schedules for all three options remain on their original terms: the 70,549-share option vests one-quarter on February 9, 2027, with the remainder vesting in monthly installments of 1/48th thereafter; the 126,999-share option vested one-quarter on June 11, 2026, with monthly installments continuing; and the 177,012-share option vested 25% on September 1, 2025, with monthly installments thereafter.

What Was Disclosed

This Form 4 discloses the repricing of three stock option grants held by Chief Medical Officer Manasi Jaiman, reducing exercise prices to $1.26 per share from $13.48, $11.29, and $4.24, subject to a one-year continuous service Retention Period condition, effective November 6, 2026.